We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Mylotarg

News List

Final NICE green light for Pfizer’s Mylotarg pharmatimes
November 19, 2018
Cost regulators for the NHS in England and Wales have now published final guidelines recommending Mylotarg, alongside daunorubicin and cytarabine
NICE expands backing for Pfizer’s Mylotarg pharmatimes
October 11, 2018
NICE is recommending Mylotarg for previously untreated, de novo, CD33-positive acute myeloid leukaemia in combination with chemotherapy.
NICE issues decision on Mylotarg, Besponsa for leukaemia pharmatimes
July 11, 2018
The National Institute for Health and Care Excellence has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid leukaemia (AML), but has asked for more information on the firm’s Besponsa for a type of acute
Withdrawn 7 years ago, Pfizer’s Mylotarg is back to market pharmatimes
September 05, 2017
US regulators have approved Pfizer’s Mylotarg as a treatment for AML after the drug was with voluntarily withdrawn from the market 7 years ago.
The curious case of Mylotarg: Pfizer’s leukaemia drug set to return pharmaphorum
July 13, 2017
Pfizer’s Mylotarg looks set for a return to the US market after FDA advisers recommended its use in acute myeloid leukaemia.